Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids

Advanced Healthcare Materials

Volumn 4, Issue 5, 2015, Pages 729-738

  Wang, Yan ^a   Hazeldine, Stuart T ^b   Li, Jing ^a   Oupický, David ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemokine receptors; Gene delivery; Polycation; Polyplexes

Indexed keywords

BONE; CONTROLLED DRUG DELIVERY; DISEASES; FUNCTIONAL POLYMERS; GENE TRANSFER; MONOMERS; TARGETED DRUG DELIVERY;

CANCER THERAPY; CHEMOKINE RECEPTORS; GENE DELIVERY; PERIPHERAL BLOOD; POLY(AMIDO AMINE); POLYCATIONS; POLYMERIC DRUGS; POLYPLEXES;

NUCLEIC ACIDS;

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; NUCLEIC ACID; POLYAMIDOAMINE; TRI TERT BUTYL 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 (CHLOROMETHYL)BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [(2 HYDROXYETHYLAMINO)METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[(2 AMINOETHYL)(TERT BUTOXYCARBONYL)AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[(3 AMINOPROPYL)(TERT BUTOXYCARBONYL)AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[TERT BUTOXYCARBONYL (2 HYDROXYETHYL)AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[TERT BUTOXYCARBONYL (3 HYDROXYPROPYL) AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[TERT BUTOXYCARBONYL [2 (1,3 DIOXOISOINDOLIN 2 YL)ETHYL]AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4 [[TERT BUTOXYCARBONYL [3 (1,3 DIOXOISOINDOLIN 2 YL)PROPYL]AMINO]METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; TRI TERT BUTYL 11 [4[(3 HYDROXYPROPYLAMINO)METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8 TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; DNA; DRUG CARRIER; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; LEUKOCYTE; LIVER CELL CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION; VALIDATION PROCESS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; DRUG CARRIERS; FEMALE; HUMANS; LEUKOCYTES; MICE; MICE, INBRED BALB C; POLYAMINES; RECEPTORS, CXCR4;

EID: 84928358014     PISSN: 21922640     EISSN: 21922659     Source Type: Journal    
DOI: 10.1002/adhm.201400608     Document Type: Article

References (43)

1. W. B. Liechty, D. R. Kryscio, B. V. Slaughter, N. A. Peppas, Annu. Rev. Chem. Biomol. Eng. 2010, 1, 149
2. H. Cabral, N. Nishiyama, K. Kataoka, Acc. Chem. Res. 2011, 44, 999.
3. J. Kopeček, Adv. Drug Delivery Rev. 2013, 65, 49
4. S. P. Schwendeman, R. B. Shah, B. A. Bailey, A. S. Schwendeman, J. Controlled Release 2014, 190, 240.
5. R. Duncan, Nat. Rev. Drug Discovery 2003, 2, 347.
6. N. D. Stebbins, M. A. Ouimet, K. E. Uhrich, Adv. Drug Delivery Rev. 2014, DOI: 10.1016/j.addr.2014.04.006.
7. L. Erdmann, K. E. Uhrich, Biomaterials 2000, 21, 1941
8. A. Prudencio, R. C. Schmeltzer, K. E. Uhrich, Macromolecules 2005, 38, 6895
9. L. Erdmann, B. Macedo, K. Uhrich, Biomaterials 2000, 21, 2507
10. J. D. Bryers, R. A. Jarvis, J. Lebo, A. Prudencio, T. R. Kyriakides, K. Uhrich, Biomaterials 2006, 27, 5039.
11. R. Rosario-Meléndez, C. L. Harris, R. Delgado-Rivera, L. Yu, K. E. Uhrich, J. Controlled Release 2012, 162, 538.
12. M. A. Ouimet, N. D. Stebbins, K. E. Uhrich, Macromol. Rapid Commun. 2013, 34, 1231
13. A. L. Carbone-Howell, N. D. Stebbins, K. E. Uhrich, Biomacromolecules 2014, 15, 1889.
14. A. L. Lakes, R. Peyyala, J. L. Ebersole, D. A. Puleo, J. Z. Hilt, T. D. Dziubla, Biomacromolecules 2014, 15, 3009
15. P. P. Wattamwar, D. Biswal, D. B. Cochran, A. C. Lyvers, R. E. Eitel, K. W. Anderson, J. Z. Hilt, T. D. Dziubla, Acta Biomater. 2012, 8, 2529
16. R. van Lith, E. K. Gregory, J. Yang, M. R. Kibbe, G. A. Ameer, Biomaterials 2014, 35, 8113.
17. Y. Zhu, J. Li, S. Kanvinde, Z. Lin, S. Hazeldine, R. K. Singh, D. Oupicky, Mol. Pharm. 2014, DOI: 10.1021/mp500469n
18. Y. Dong, Y. Zhu, J. Li, Q.-H. Zhou, C. Wu, D. Oupický, Mol. Pharm. 2012, 9, 1654
19. J. Li, Y. Zhu, S. T. Hazeldine, C. Li, D. Oupicky, Angew. Chem. Int. Ed. 2012, 51, 8740.
20. R. Duncan, M. J. Vicent, Adv. Drug Delivery Rev. 2013, 65, 60
21. K. Wu, J. Liu, R. N. Johnson, J. Yang, J. Kopeček, Angew. Chem. Int. Ed. 2010, 49, 1451.
22. G. M. Chertow, S. K. Burke, J. Michael Lazarus, K. H. Stenzel, D. Wombolt, D. Goldberg, J. V. Bonventre, E. Slatopolsky, Am. J. Kidney Dis. 1997, 29, 66
23. D. Tyssen, S. A. Henderson, A. Johnson, J. Sterjovski, K. Moore, J. La, M. Zanin, S. Sonza, P. Karellas, M. P. Giannis, G. Krippner, S. Wesselingh, T. McCarthy, P. R. Gorry, P. A. Ramsland, R. Cone, J. R. A. Paull, G. R. Lewis, G. Tachedjian, PLoS One 2010, 5, e12309.
24. J. Li, D. Oupicky, Biomaterials 2014, 35, 5572
25. Y. Wang, J. Li, D. Oupicky, Pharm. Res. 2014, 12, 3538.
26. M. Brave, A. Farrell, S. C. Lin, T. Ocheltree, S. P. Miksinski, S. L. Lee, H. Saber, J. Fourie, C. Tornoe, B. Booth, W. S. Yuan, K. He, R. Justice, R. Pazdur, Oncology 2010, 78, 282.
27. D. Hanahan, Robert A. Weinberg, Cell 2011, 144, 646
28. I. J. Fidler, Nat. Rev. Cancer 2003, 3, 453.
29. F. R. Balkwill, J. Pathol. 2012, 226, 148
30. T. Gangadhar, S. Nandi, R. Salgia, Cancer Biol. Ther. 2010, 9, 409
31. O. Wald, U. Izhar, G. Amir, S. Avniel, Y. Bar-Shavit, H. Wald, I. D. Weiss, E. Galun, A. Peled, J. Immunol. 2006, 177, 6983
32. O. Wald, U. Izhar, G. Amir, S. Kirshberg, Z. Shlomai, G. Zamir, A. Peled, O. M. Shapira, J. Thorac. Cardiovasc. Surg. 2011, 141, 1503.
33. A. Zlotnik, A. M. Burkhardt, B. Homey, Nat. Rev. Immunol. 2011, 11, 597.
34. M. Burger, A. Glodek, T. Hartmann, A. Schmitt-Graff, L. E. Silberstein, N. Fujii, T. J. Kipps, J. A. Burger, Oncogene 2003, 22, 8093.
35. A. Egorova, A. Kiselev, M. Hakli, M. Ruponen, V. Baranov, A. Urtti, J. Gene Med. 2009, 11, 772.
36. G. J. Bridger, R. T. Skerlj, P. E. Hernandez-Abad, D. E. Bogucki, Z. Wang, Y. Zhou, S. Nan, E. M. Boehringer, T. Wilson, J. Crawford, M. Metz, S. Hatse, K. Princen, E. De Clercq, D. Schols, J. Med. Chem. 2010, 53, 1250.
37. V. Bodart, V. Anastassov, M. C. Darkes, S. R. Idzan, J. Labrecque, G. Lau, R. M. Mosi, K. S. Neff, K. L. Nelson, M. C. Ruzek, Biochem. Pharmacol. 2009, 78, 993
38. M. M. Rosenkilde, L.-O. Gerlach, S. Hatse, R. T. Skerlj, D. Schols, G. J. Bridger, T. W. Schwartz, J. Biol. Chem. 2007, 282, 27354.
39. S. Hatse, K. Princen, G. Bridger, E. De Clercq, D. Schols, FEBS Lett. 2002, 527, 255.
40. A. Zuk, M. Gershenovich, Y. Ivanova, R. T. MacFarland, S. P. Fricker, S. R. Ledbetter, Am. J. Physiol. Renal Physiol. 2014, 307, F783.
41. H. E. Broxmeyer, C. M. Orschell, D. W. Clapp, G. Hangoc, S. Cooper, P. A. Plett, W. C. Liles, X. Li, B. Graham-Evans, T. B. Campbell, G. Calandra, G. Bridger, D. C. Dale, E. F. Srour, J. Exp. Med. 2005, 201, 1307.
42. L. Parhamifar, A. K. Larsen, A. C. Hunter, T. L. Andresen, S. M. Moghimi, Soft Matter 2010, 6, 4001.
43. J. Li, Y. Wang, Y. Zhu, D. Oupicky, J. Controlled Release 2013, 172, 589-600.